This phase II trial is testing a new biological therapy (V937, given as an injection or into the vein, in combination with immunotherapy) and comparing it with standard immunotherapy alone, in patients with advanced melanoma.
This trial is treating patients with melanoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 2, Randomized Clinical Study of Intravenous or Intratumoral Administration of V937 in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma
Eligible patients will be randomised to receive V937 (either as an intravenous infusion or intratumoural injection) in combination with 200mg intravenous Pembrolizumab OR 200mg intravenous Pembrolizumab alone. V937 will be administered for up to 8 cycles (up to 6 months). Pembrolizumab will be administered for up to 35 cycles (up to 2 years).
Recruiting Hospitals Read More